Cnj-016 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to smallpox vaccination adverse event management, biodefense preparedness initiatives, plasma fractionation advancements, regulatory emergency approvals, public health emergency planning.

The growth in the forecast period can be attributed to renewed biodefense investments, expansion of national stockpiles, improved plasma collection networks, rising immunocompromised populations, global health security strategies. Major trends in the forecast period include increased preparedness for smallpox vaccine complications, strategic stockpiling of vaccinia immune globulin, focus on immunocompromised patient safety, government led biodefense programs, expansion of plasma derived antibody therapies.

The increasing prevalence of immunodeficiency diseases is expected to propel the growth of the CNJ-016 market in the coming years. Immunodeficiency diseases are conditions in which the immune system is weakened or unable to respond effectively, making patients more susceptible to infections and diseases. The rise in immunodeficiency is driven by genetic factors, environmental influences, and specific medical conditions or treatments. CNJ-016, a vaccinia immune globulin, supports patients with immunodeficiency diseases by providing passive immunity, protecting against complications such as eczema vaccinatum, progressive vaccinia, and other vaccinia virus-related adverse events, particularly in individuals with compromised immune systems. For example, in November 2025, Immunodeficiency UK, a UK-based charity, reported that over 5,000 people in the United Kingdom were documented as having one of more than 450 identified primary immunodeficiency conditions in 2025, most of which are genetic disorders present from birth. Therefore, the increasing prevalence of immunodeficiency diseases is driving the growth of the CNJ-016 market.

The increasing focus on personalized medicine is expected to further drive the growth of the CNJ-016 market. Personalized medicine is an approach that tailors medical treatments and therapies according to a patient’s genetic makeup, environment, and lifestyle. Its adoption is rising due to advancements in genomic technologies, improved access to big data analytics, and the availability of therapies specifically designed for individual genetic profiles. CNJ-016 provides targeted treatment for individuals with compromised immune systems, helping reduce the risk of complications from vaccinations or viral infections based on their unique immune profiles and medical needs. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the USFDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the CNJ-016 market.

The rise in smallpox vaccination is expected to propel the growth of the CNJ-016 market. Smallpox vaccination involves administering a vaccine to provide immunity against smallpox, a highly contagious and potentially lethal viral disease caused by the variola virus. Global smallpox vaccination efforts are increasing due to concerns over the potential reemergence of infectious diseases. CNJ-016 supports smallpox vaccination by offering passive immunity to individuals with weakened immune systems or those at risk of vaccinia virus complications. For example, in May 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported that 1.2 million doses of JYNNEOS had been administered, achieving approximately 37% first-dose coverage and 23% second-dose coverage among the estimated at-risk population. Therefore, the rise in smallpox vaccination is driving the growth of the CNJ-016 market.

Major companies operating in the cnj-016 market are Emergent Biosolutions Inc.

North America was the largest region in the cnj-016 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cnj-016 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cnj-016 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the cnj-016 market by increasing costs associated with plasma sourcing, antibody purification materials, and cold chain logistics. These impacts are most visible in government procurement programs and hospital based emergency treatment settings in north america and europe. Import duties have added pressure to stockpiling budgets for biodefense therapies. Regulatory clearance timelines have also been affected by cross border trade controls. At the same time, tariffs are encouraging domestic plasma fractionation and strengthening national preparedness capabilities.

The cnj-016 market research report is one of a series of new reports that provides cnj-016 market statistics, including cnj-016 industry global market size, regional shares, competitors with a cnj-016 market share, detailed cnj-016 market segments, market trends and opportunities, and any further data you may need to thrive in the cnj-016 industry. This cnj-016 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

CNJ-016 is a vaccinia immune globulin (VIG) product, a biologic therapy used to manage severe complications from smallpox vaccination, such as eczema vaccinatum. Derived from human plasma, it is rich in antibodies against the vaccinia virus and is primarily used for patients who experience life-threatening reactions to the virus, including those with eczema or weakened immune systems.

The main clinical indications for CNJ-016 include eczema vaccinatum, progressive vaccinia, and severe generalized vaccinia. Eczema vaccinatum is a rare but serious complication that can occur in individuals with eczema (atopic dermatitis) following exposure to the vaccinia virus, often through smallpox vaccination. CNJ-016 is distributed via direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and is used by hospitals, clinics, and home care providers.

The cnj-016 market consists of sales of human immune globulin and Vaccinia immune globulin intravenous. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.